Henderson G S, Brown K A, Perkins S L, Abbott T M, Clayton F
Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, USA.
Mod Pathol. 1996 Apr;9(4):430-8.
The bcl-2 protein, which protects cells from apoptosis, is normally expressed in a number of adult tissues. Dysregulated bcl-2 expression, secondary to (14;18) chromosomal translocation, seems to promote the development of follicular lymphomas, and recent findings of bcl-2 protein in several solid tumors suggest that it might contribute to the genesis of many other neoplasms. bcl-2 is also highly expressed in normal proliferative endometrium and markedly down-regulated in secretory endometrium, which suggests that its expression is estrogen regulated. Because the development of most endometrial carcinomas is associated with hyperestrogenic states, we began the investigation of the role of bcl-2 in endometrial carcinogenesis by immunohistochemically quantifying its expression in proliferative, hyperplastic, atypically hyperplastic, and carcinomatous endometrium. The results of this study show that bcl-2 is relatively highly expressed in proliferative (n = 11) and hyperplastic (n = 18) endometrium, with respective mean staining scores of 3.59 and 3.47 (scale, 0-4), but is significantly (P < 0.001) down-regulated in atypical hyperplasia (n = 11; score, 0.82), and adenocarcinoma (n = 34; score, 0.86). bcl-2 expression did not correlate with stage, grade, estrogen-receptor, or progesterone-receptor expression. Polymerase chain reaction analyses of DNA isolated from several endometrial carcinomas were negative for (14;18) translocation involving the bcl-2 gene. Thus, bcl-2 apparently plays no role in the progression of atypical hyperplasia to carcinoma or in the development of high-grade or advanced-stage endometrial carcinoma. These results, however, do not rule out the involvement of bcl-2 in very early, preatypical hyperplasia phases of endometrial carcinogenesis. Finally, the marked difference in bcl-2 expression in hyperplastic and atypically hyperplastic glands might prove to be diagnostically useful in the often difficult distinction of these entities.
bcl-2蛋白可保护细胞免于凋亡,通常在多种成人组织中表达。继发于(14;18)染色体易位的bcl-2表达失调似乎促进了滤泡性淋巴瘤的发展,最近在几种实体瘤中发现bcl-2蛋白表明它可能与许多其他肿瘤的发生有关。bcl-2在正常增殖期子宫内膜中也高度表达,而在分泌期子宫内膜中明显下调,这表明其表达受雌激素调节。由于大多数子宫内膜癌的发生与高雌激素状态有关,我们通过免疫组化定量bcl-2在增殖期、增生期、非典型增生期和癌性子宫内膜中的表达,开始研究bcl-2在子宫内膜癌发生中的作用。这项研究结果表明,bcl-2在增殖期(n = 11)和增生期(n = 18)子宫内膜中相对高度表达,平均染色评分分别为3.59和3.47(范围0 - 4),但在非典型增生(n = 11;评分0.82)和腺癌(n = 34;评分0.86)中显著下调(P < 0.001)。bcl-2表达与分期、分级、雌激素受体或孕激素受体表达无关。对从几种子宫内膜癌中分离的DNA进行聚合酶链反应分析,结果显示涉及bcl-2基因的(14;18)易位为阴性。因此,bcl-2显然在非典型增生向癌的进展过程中或在高级别或晚期子宫内膜癌的发展中不起作用。然而,这些结果并不排除bcl-2参与子宫内膜癌发生的非常早期、非典型增生前期阶段。最后,增生性和非典型增生性腺体中bcl-2表达的显著差异可能在这些实体的鉴别诊断中具有重要意义,而这些实体的鉴别往往很困难。